Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
27
05
2022
accepted:
26
08
2022
pmc-release:
01
05
2024
medline:
19
4
2023
pubmed:
2
9
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia in the setting of oxidative stress, which can be caused by medication exposure. Regulatory agencies worldwide warn against the use of certain medications in persons with G6PD deficiency, but in many cases, this information is conflicting, and the clinical evidence is sparse. This guideline provides information on using G6PD genotype as part of the diagnosis of G6PD deficiency and classifies medications that have been previously implicated as unsafe in individuals with G6PD deficiency by one or more sources. We classify these medications as high, medium, or low to no risk based on a systematic review of the published evidence of the gene-drug associations and regulatory warnings. In patients with G6PD deficiency, high-risk medications should be avoided, medium-risk medications should be used with caution, and low-to-no risk medications can be used with standard precautions, without regard to G6PD phenotype. This new document replaces the prior Clinical Pharmacogenetics Implementation Consortium guideline for rasburicase therapy in the context of G6PD genotype (updates at: www.cpicpgx.org).
Identifiants
pubmed: 36049896
doi: 10.1002/cpt.2735
pmc: PMC10281211
mid: NIHMS1840084
doi:
Substances chimiques
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Types de publication
Systematic Review
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-985Subventions
Organisme : NIGMS NIH HHS
ID : R24 GM115264
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM123930
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010615
Pays : United States
Informations de copyright
© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.
Références
J Pediatr. 2012 Sep;161(3):571; author reply 571-2
pubmed: 22795224
Blood Cells Mol Dis. 2012 Mar 15;48(3):154-65
pubmed: 22293322
Front Pharmacol. 2021 Mar 15;12:638885
pubmed: 33790795
J Pediatr. 2012 Aug;161(2):191-6.e1
pubmed: 22459229
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Br Med J. 1976 Nov 20;2(6046):1227-9
pubmed: 990860
Blood. 1994 Dec 1;84(11):3613-36
pubmed: 7949118
Lancet. 1975 Feb 15;1(7903):410
pubmed: 46571
Blood. 2020 Sep 10;136(11):1225-1240
pubmed: 32702756
Pharmacogenet Genomics. 2022 Apr 1;32(3):87-93
pubmed: 34693927
Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78
pubmed: 19233695
Am J Perinatol. 2011 May;28(5):405-12
pubmed: 21365530
World Health Organ Tech Rep Ser. 1967;366:1-53
pubmed: 4963040
Genet Med. 2012 Apr;14(4):424-31
pubmed: 22361898
Rev Infect Dis. 1987 Mar-Apr;9 Suppl 2:S218-29
pubmed: 3495027
N Engl J Med. 2018 Jan 4;378(1):60-71
pubmed: 29298156
Expert Opin Pharmacother. 2002 Apr;3(4):433-42
pubmed: 11934348
Blood Rev. 2007 Sep;21(5):267-83
pubmed: 17611006
EMBO J. 2002 Aug 15;21(16):4229-39
pubmed: 12169625
Am J Hum Genet. 1967 Nov;19(6):757-61
pubmed: 6075369
FASEB J. 1994 Feb;8(2):174-81
pubmed: 8119488
Drug Saf. 2010 Sep 1;33(9):713-26
pubmed: 20701405
Ann Pharmacother. 2013 Oct;47(10):1353-8
pubmed: 24259700
Ann Clin Biochem. 1994 Jan;31 ( Pt 1):50-5
pubmed: 8154852
Bull World Health Organ. 2019 Jun 01;97(6):394-404C
pubmed: 31210677
Clin Pharmacol Ther. 2014 Aug;96(2):169-74
pubmed: 24787449
Br J Haematol. 2009 Jun;145(6):680
pubmed: 19076170
J Lab Clin Med. 1969 Feb;73(2):283-90
pubmed: 4974311
Science. 1956 Sep 14;124(3220):484-5
pubmed: 13360274
Br J Haematol. 1998 Jun;101(4):670-5
pubmed: 9674740
Isr J Med Sci. 1975 Apr;11(4):340-6
pubmed: 1140951
N Engl J Med. 2019 Jan 17;380(3):215-228
pubmed: 30650322
Br J Clin Pharmacol. 2017 Jan;83(1):211-212
pubmed: 27650490
J Am Med Assoc. 1952 Aug 23;149(17):1568-70
pubmed: 14945981
Tohoku J Exp Med. 1965 Apr 25;85:248-51
pubmed: 14323978
Pharmacogenomics J. 2019 Jun;19(3):305-314
pubmed: 30206300
Bull World Health Organ. 1989;67(6):601-11
pubmed: 2633878
DICP. 1990 Dec;24(12):1210-3
pubmed: 2089833
Leukemia. 2003 Mar;17(3):499-514
pubmed: 12646938
Blood. 2012 Nov 15;120(20):4123-33
pubmed: 22993389
Pediatrics. 2013 Jan;131(1):e309-12
pubmed: 23209099
J Pediatr. 2012 Aug;161(2):197-200
pubmed: 22494872
Bull World Health Organ. 1971;45(2):243-53
pubmed: 5316621
Eur J Pediatr. 2001 Mar;160(3):195
pubmed: 11277384